Suppr超能文献

基于中位数的增量成本效益比(ICER)。

Median-Based Incremental Cost-Effectiveness Ratio (ICER).

作者信息

Bang Heejung, Zhao Hongwei

机构信息

Division of Biostatistics, Department of Public Health Sciences, University of California, Davis, CA, USA.

出版信息

J Stat Theory Pract. 2012;6(3):428-442. doi: 10.1080/15598608.2012.695571. Epub 2012 Aug 10.

Abstract

Cost-effectiveness analysis (CEA) is a type of economic evaluation that examines the costs and health outcomes of alternative strategies and has been extensively applied in health sciences. The incremental cost-effectiveness ratio (ICER), which represents the additional cost of one unit of outcome gained by one strategy compared with another, has become a popular methodology in CEA. Despite its popularity, limited attention has been paid to summary measures other than the mean for summarizing cost as well as effectiveness in the context of CEA. Although some apparent advantages of other central tendency measures such as median for cost data that are often highly skewed are well understood, thus far, the median has rarely been considered in the ICER. In this paper, we propose the median-based ICER, along with inferential procedures, and suggest that mean and median-based ICERs be considered together as complementary tools in CEA for informed decision making, acknowledging the pros and cons of each. If the mean and median-based CEAs are concordant, we may feel reasonably confident about the cost-effectiveness of an intervention, but if they provide different results, our confidence may need to be adjusted accordingly, pending further evidence.

摘要

成本效益分析(CEA)是一种经济评估类型,它考察替代策略的成本和健康结果,并且已在健康科学领域得到广泛应用。增量成本效益比(ICER)代表一种策略相对于另一种策略获得单位结果的额外成本,它已成为成本效益分析中一种流行的方法。尽管它很受欢迎,但在成本效益分析的背景下,除了均值之外,用于汇总成本和效益的汇总指标受到的关注有限。虽然人们很清楚其他集中趋势指标(如中位数)对于经常高度偏态的成本数据有一些明显优势,但到目前为止,中位数在增量成本效益比中很少被考虑。在本文中,我们提出基于中位数的增量成本效益比以及推断程序,并建议将基于均值和中位数的增量成本效益比作为成本效益分析中的补充工具一起考虑,以便做出明智的决策,同时认识到每种方法的优缺点。如果基于均值和中位数的成本效益分析结果一致,我们可能对一项干预措施的成本效益有合理的信心,但如果它们给出不同的结果,在有进一步证据之前,我们的信心可能需要相应调整。

相似文献

1
Median-Based Incremental Cost-Effectiveness Ratio (ICER).
J Stat Theory Pract. 2012;6(3):428-442. doi: 10.1080/15598608.2012.695571. Epub 2012 Aug 10.
3
Cost-effectiveness analysis: a proposal of new reporting standards in statistical analysis.
J Biopharm Stat. 2014;24(2):443-60. doi: 10.1080/10543406.2013.860157.
6
Industry sponsorship bias in cost effectiveness analysis: registry based analysis.
BMJ. 2022 Jun 22;377:e069573. doi: 10.1136/bmj-2021-069573.
8
A cost-effectiveness analysis of freeze-only or fresh embryo transfer in IVF of non-PCOS women.
Hum Reprod. 2018 Oct 1;33(10):1907-1914. doi: 10.1093/humrep/dey253.
9
A non-stationary Markov model for economic evaluation of grass pollen allergoid immunotherapy.
PLoS One. 2020 May 14;15(5):e0232753. doi: 10.1371/journal.pone.0232753. eCollection 2020.
10
The impact of increased post-progression survival on the cost-effectiveness of interventions in oncology.
Clinicoecon Outcomes Res. 2019 May 3;11:309-324. doi: 10.2147/CEOR.S191382. eCollection 2019.

引用本文的文献

2
Cost-Effectiveness of the Pneumococcal Vaccine in the Adult Population: A Systematic Review.
Healthcare (Basel). 2024 Dec 9;12(23):2490. doi: 10.3390/healthcare12232490.
3
Cost-effectiveness of human papillomavirus (HPV) vaccination in Tunisia: a modelling study.
BMJ Open. 2024 Dec 5;14(12):e085462. doi: 10.1136/bmjopen-2024-085462.
5
Comparison of statistical methods for the analysis of patient-reported outcomes in randomised controlled trials: A simulation study.
Stat Methods Med Res. 2024 Nov;33(11-12):1920-1938. doi: 10.1177/09622802241275361. Epub 2024 Oct 23.
6
Cost-Effectiveness Analysis of Pneumococcal Vaccines in the Pediatric Population: A Systematic Review.
Healthcare (Basel). 2024 Sep 29;12(19):1950. doi: 10.3390/healthcare12191950.
9
Cost-effectiveness of the Perioperative Pain Management Bundle a registry-based study.
Front Public Health. 2023 Sep 7;11:1157484. doi: 10.3389/fpubh.2023.1157484. eCollection 2023.

本文引用的文献

1
Nonparametric inference for median costs with censored data.
Biometrics. 2012 Sep;68(3):717-25. doi: 10.1111/j.1541-0420.2012.01755.x. Epub 2012 Feb 24.
2
Update on statistical power and sample size assessments for cost-effectiveness studies.
Expert Rev Pharmacoecon Outcomes Res. 2004 Feb;4(1):89-98. doi: 10.1586/14737167.4.1.89.
3
A study on confidence intervals for incremental cost-effectiveness ratios.
Biom J. 2008 Aug;50(4):505-14. doi: 10.1002/bimj.200810439.
4
Show me the data.
J Cell Biol. 2007 Dec 17;179(6):1091-2. doi: 10.1083/jcb.200711140.
5
On the equivalence of some medical cost estimators with censored data.
Stat Med. 2007 Oct 30;26(24):4520-30. doi: 10.1002/sim.2882.
6
Nonparametric statistical methods for cost-effectiveness analyses.
Biometrics. 2006 Jun;62(2):576-88. doi: 10.1111/j.1541-0420.2006.00509.x.
8
Why don't Americans use cost-effectiveness analysis?
Am J Manag Care. 2004 May;10(5):308-12.
10
Median regression with censored cost data.
Biometrics. 2002 Sep;58(3):643-9. doi: 10.1111/j.0006-341x.2002.00643.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验